Your session is about to expire
← Back to Search
Ultrasound Therapy
ExAblate 4000 - Type 2 for Brain Tumor
N/A
Waitlist Available
Led By Graeme Woodworth, MD
Research Sponsored by InSightec
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at the time of the exablate mrgfus procedure
Awards & highlights
Study Summary
This trial is testing a new way to treat brain cancer by temporarily disrupting the blood brain barrier.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ at the time of the exablate mrgfus procedure and 24 hours post-procedure
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at the time of the exablate mrgfus procedure and 24 hours post-procedure
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Device and procedure related adverse events
Secondary outcome measures
Feasibility of BBB disruption
Trial Design
1Treatment groups
Experimental Treatment
Group I: ExAblate 4000 - Type 2Experimental Treatment1 Intervention
ExAblate BBBD
Find a Location
Who is running the clinical trial?
InSightecLead Sponsor
89 Previous Clinical Trials
3,699 Total Patients Enrolled
Graeme Woodworth, MDPrincipal InvestigatorUniversity of Maryland
2 Previous Clinical Trials
140 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Share this study with friends
Copy Link
Messenger